IMIDomics Inc., a San Francisco, CA-based drug discovery company focused on patients with immune-mediated inflammatory diseases (IMIDs), completed a $16.5m Series A financing round.
The round was led by DNS Capital with additional investment from Bristol Myers Squibb, The Pritzker Organization, Tao Capital and others.
The company intends to use the funds to accelerate its precision discovery efforts and accelerate technologies that are critical to the further development of new IMID treatments, while expanding teams in the US and Europe.
Founded in 2015, following a decade of incubation within Vall d’Hebron Hospital in Barcelona, during which the IMID-Biobank was built, and relocated to the United States in 2021, IMIDomics is a biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs). The company’s Precision Discovery Platform combines and analyzes clinical, epidemiologic, and biomolecular data to uncover new insights about IMIDs including lupus, Crohn’s disease, rheumatoid arthritis, and ulcerative colitis.
Founded in Barcelona in 2015 by Dr. Sara Marsal, Head of the Rheumatology Department at the Vall d’Hebron University Hospital, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology, the company is led by Juan Harrison, President and CEO.
FinSMEs
27/07/2021